Episode 203 - November 13, 2026
Summary
- XBI’s roughly 25% year-to-date gain masks a market still punishing binary risk and financing needs. Investors favor commercial businesses with a valuation floor plus pipeline upside, while commercial names without pipeline can remain value traps. Werber’s cautious optimism depends on broader market stability; two expected rate hikes and a substantial AI unwind could overwhelm biotech’s defensive appeal. “Nobody wants to play binaries,” Schmidt says.
- FDA confidence rests on predictable decisions, adequate staffing and leadership continuity. The agency has approved 47 new molecular entities through October despite leadership uncertainty. Matteis reports that Scott Gottlieb expects Dr. Overton’s confirmation, but anticipates limited immediate policy change; without confirmation, “there’s really no plan B.” Haviland’s priority is consistency: developers struggle when regulatory goalposts move.
- Gottlieb sees China’s strengthening bargaining position closing the earlier licensing arbitrage. Matteis relays that business-development teams are already active, local financing supports further development, and some counterparties seek 50/50 cost and upside sharing. The “arbitrage opportunity here is already closed,” in Gottlieb’s assessment, leaving US development speed as a more relevant competitive question.
- MFN creates potential US pricing risk even as companies reduce their dependence on overseas revenue. Werber puts ex-US sales around 20% for novel launches, versus 60% in some historical cases; Matteis worries more about existing franchises with large geographic price gaps. Schmidt counters that rare disease can still depend heavily on international sales, while Haviland recalls overseas prices at “a very small fraction of the US price” despite strong innovation scores.
- Launch forecasts can mistake expert enthusiasm for representative prescribing behavior. Cobenfy surveys suggested a blockbuster trajectory, while Ionis reported $9 million against $20 million quarterly consensus as its market expanded into severe hypertriglyceridemia. Access delays, free drug and slow patient identification complicate conversion into revenue. Werber’s conclusion: “The more we do this, the more we realize how little we know.”
- Blueprint’s conviction preceded external guidance because management triangulated several imperfect sources of evidence. Haviland describes fieldwork, independent physician research and claims analysis supporting a potential blockbuster market, which Blueprint described publicly as north of $1 billion. Guidance still required quarterly judgment about coverage, prescribing and revenue conversion: “It’s an art more than a science.”
- The last mile of diagnostics and practice workflow can defeat compelling efficacy. Haviland acknowledges that Blueprint and others overestimated RET-driven lung cancer launches despite approximately 80% response rates and 30% complete responses. A two-week molecular-testing delay can lead an anxious patient onto another treatment first. “Physician habit change is really hard, and the last mile matters a lot.”
- PepGen’s DM1 results strengthen the splicing-to-function story while leaving pivotal confirmation ahead. Higher-dose data showed almost 50% splicing improvement versus roughly 10–30% in other programs, with encouraging functional measures, but small numbers and potential renal toxicity remain important caveats. Matteis sees possible positive readthrough for Dyne’s antisense approach; its accelerated-approval study reads out early next year and remains “pretty binary.”
Deep dive
1. Biotech buyers are paying for commercial value floors
- Schmidt puts XBI roughly 25% higher for the year, yet buy-side clients are struggling and often lagging the index. Earnings, clinical results and ordinary updates mostly prompted selling this week; one IPO failed to get through. Matteis sees demand for a commercial business with a “semi-objective thing you can value” plus pipeline upside. Commercial businesses without pipeline, however, can still trade like value traps.
- Werber’s tension is defensive rotation versus interest-rate pressure: the blue wave appears to help large-cap biotech as AI weakens, but markets are pricing two more rate hikes. He remains “cautiously optimistic,” conditional on broader stabilization; a major AI unwind would create too much disruption for biotech. M&A is a tailwind, though usually insufficient to drive the sector without substantial deal volume.
- Haviland qualifies the funding pessimism: some recent IPOs involved earlier-stage programs, although those deals were harder to complete and the class generally traded poorly. Matteis notes that much of the mature backlog has listed, suggesting greater selectivity ahead. Haviland, involved in a reverse merger herself, says that market still looks “pretty hot.”
2. FDA confidence rests on consistent rules and more staff
- With Dr. Overton’s confirmation vote expected on the 18th, Schmidt counts 47 new molecular entities approved through October—more than in 35 of the previous 41 years—with a possible shot at the 59-approval record. Matteis reports that Scott Gottlieb was more optimistic than expected about confirmation: Overton’s meetings with outgoing senators Cassidy and Susan Collins suggested they considered the process worth pursuing.
- Schmidt’s pushback is practical: if acting leadership has restored stability, what changes? Matteis’s answer: “It didn’t sound like a lot would change.” Returning advisory committees and more consistent sponsor feedback are already improvements. Gottlieb emphasized rehiring and expertise after DOGE cuts, with possible marginal acceleration around toxicology requirements. Without confirmation, “there’s really no plan B” for avoiding an extended period of acting commissioners.
- For Haviland, “predictability is the number one thing we’re looking for”: developers can navigate a difficult regulator but struggle when goalposts move. Modernization follows dependable, science-driven leadership. Matteis still sees uncertainty in rare disease, where coming decisions should clarify whether the agency is closer to the Peter Marks approach or Prasad’s.
3. China arbitrage narrows as MFN constrains geographic strategy
- Gottlieb’s China assessment, relayed by Matteis, is that the legislative response around the COINS Act lags commercial reality: the “arbitrage opportunity here is already closed.” Business-development teams are active, local capital markets let companies take assets further, and some seek 50/50 development-cost and upside sharing. He sounded less concerned about the US competitive threat than a year ago; the remaining question is how FDA can safely enable faster US proof-of-concept work.
- On pricing, Matteis relays Gottlieb’s speculation that Trump might find agreement with Democrats most easily on drug costs, reviving MFN. Scope, carve-outs and treatment of new drugs remain unknown. Some launch prices have recently been 20–50% above consensus. Werber challenges the incremental threat: ex-US sales, once around 60% in some cases, now represent roughly 20% for novel launches. “Are we not already, uh, MFN’d essentially now?”
- Matteis distinguishes lower ex-US forecasts from a potential US price reset for established franchises with large geographic price gaps. Schmidt challenges the idea that overseas revenue barely matters: Scholar Rock expects a majority of sales outside the US, citing severity and unmet need. Haviland supplies Blueprint’s counterexample: even rare-disease products with “incredible innovation scores” secured prices that were “a very small fraction of the US price.”
- Haviland says companies she advises assume MFN remains in the debate across administrations, constraining licensing choices. She and Matteis believe licensing to another pharma company would still leave foreign prices relevant to MFN. Confidential discounts and annual revenue caps complicate comparisons. Werber questions durability under a future CMS; Schmidt notes sunset provisions and undisclosed agreement details.
4. Launch forecasts overread the physicians they survey
- Matteis’s forecast misses include Cobenfy, where surveys suggested “it was a monster,” and Alnylam, whose still-good launch fell short of heightened expectations. Expert-network physicians may be unusually data-engaged and risk-tolerant. In schizophrenia, many new prescriptions come from nurse practitioners and mental-health facilities, not necessarily the experts being polled. Analysts and investors may all be interviewing the same unrepresentative handful—a form of “mispolling,” particularly without useful sales analogs.
- Werber’s Ionis example makes the access problem concrete: Q3 sales were $9 million against $20 million consensus as the drug expanded into severe hypertriglyceridemia, following $5 million the prior quarter in rare FCS. Initial patient conversion was small, probably with considerable free drug. Management now expects essentially flat Q4 while practices build awareness; guidance was cut roughly in half. Both Ionis and Arrowhead fell despite warnings that adoption would take time.
- Schmidt criticizes optimistic corporate materials and cherry-picked KOLs; Matteis adds that predominantly buy-rated analyst coverage can inadvertently raise expectations. Haviland counters that bearish coverage can also provide a platform for “narrative arbitrage” around earnings. Some companies carefully explain access delays and partial-quarter treatment; others say little. Werber favors repeated physician tracking, potentially with the same respondents quarterly or every six months.
5. Blueprint’s conviction preceded the guidance investors saw
- Haviland separates confidence in peak opportunity from visibility into the route there. Blueprint began seriously examining indolent systemic mastocytosis in 2016, then deepened claims-data work, patient-journey analysis and AI-assisted searches for undiagnosed patients in 2020–2021. Those sources created conviction before launch. Translating a new patient-reported endpoint into an exact clinically meaningful point change, however, risked “a false level of precision.”
- Blueprint deliberately did not claim a $4–5 billion market; Haviland said the company described it externally as a blockbuster opportunity, north of $1 billion. Even that drew skepticism. It updated market-size views annually at JPMorgan, raising estimates alongside demonstrated revenue growth. “We had conviction much earlier than we guided externally,” Haviland says; the growing sales line made subsequent revisions more credible.
- Schmidt asks how management used the gap between internal confidence and Street forecasts. Haviland says guidance was heavily debated: investors draw a line from launch to a peak seven or eight years out, while each quarter reflects a range of outcomes. Management had to express confidence in that opportunity while allowing several plausible quarterly results to remain consistent with the longer trajectory.
- Revenue conversion changes with payer mix, time to coverage, free-drug use, seasonality and geographic expansion. Patients can migrate from commercial insurance into Medicare or Medicaid, and annual reauthorization can change the mix again. Haviland emphasizes that managing expectations and investor psychology requires learned skills; those skills do not follow automatically from successfully developing a medicine.
6. Reliable guidance combines field intelligence with independent data
- An unidentified speaker asks whether grateful physicians tell companies what they want to hear—surveys sometimes receive a 50% haircut. Haviland’s answer is triangulation. She visited the field quarterly, including ordinary treaters rather than only academic KOLs, and combined those encounters with independent research across hundreds of physicians and claims-based modeling. “We needed all three.” No individual source provided enough accuracy to support guidance.
- Her warning about expert networks is concrete: Blueprint sometimes saw self-described ISM experts offering calls despite claims data showing no ISM patients seen in five years. She acknowledges that the data could be wrong, but the expertise claim deserved scrutiny. The claims infrastructure also supported machine-learning searches for likely patients and real-time field targeting.
- One operational obstacle: a practice does its business with Quest, but the needed assay sits at Labcorp. Testing may be accessible eventually; changing workflows takes time. Haviland’s answer is to do both jobs—help today’s patient obtain testing and get the assay into the lab the broader prescriber base already uses.
- Werber asks whether guidance comes from top-down market-share estimates or territory-level forecasts. Haviland says mostly bottom-up, informed by territory feedback and sophisticated modeling, then reconciled with recent growth and executive judgment. Sales teams may preserve “a little dry powder” to beat targets. Management checks new starts, repeat and new prescribers, persistence, refill rates and payer dynamics before challenging territories with an achievable growth view: “realistic, pragmatic, but optimistic.”
7. Compelling efficacy still stalls at the last mile
- Haviland’s admission is blunt: “We got it wrong at Blueprint,” alongside Roche, Lilly and Loxo in RET-driven lung cancer. Drugs with roughly 80% response rates and 30% complete responses failed to meet commercial expectations. A newly diagnosed, anxious patient may start immunotherapy while waiting two weeks for molecular results, then perhaps receive targeted therapy later. Strong efficacy did not remove the diagnostic delays and practice habits affecting treatment sequencing.
- Werber sees similar problems in ROS1 and G12C. Amgen warned that 14% G12C prevalence and mutations documented in medical records did not guarantee prescribing: doctors may not know the result is there. Haviland’s “postage stamp-sized break room” captures the environment—an oncologist has fifteen minutes amid a waiting room full of very sick patients. “Physician habit change is really hard, and the last mile matters a lot.”
- Haviland says that in much of oncology, 70% of patients are treated in the community, qualifying that patterns differ by tumor and medicine. Werber recalls experts saying lung, breast, prostate and colon account for 90% of community volume. Embedding treatments in practice pathways and electronic records can help, but takes time. “Practice economics matter” too: dispensing margins and existing infusion centers influence businesses that must pay staff.
- Testing can fail the launch. Blueprint’s KIT D816V mutation was not detected sensitively enough by major panels, requiring a specific assay and education about which test to use. A blood-based option expanded access by avoiding invasive procedures such as bone-marrow sampling that some patients resist. Haviland qualifies her lung-cancer comments: she has been out of that field for years and cannot give current ROS1 or RET panel sensitivities.
8. PepGen’s splicing signal leaves pivotal confirmation ahead
- Matteis highlights PepGen’s higher-dose peptide-conjugate data in myotonic dystrophy type 1: almost 50% improvement in muscle splicing versus roughly 10–30% in other programs, alongside encouraging functional endpoints. He describes the strongest splicing impact seen, while stressing the small sample and potential renal toxicity of peptide conjugates. Splicing remains at least a directional biomarker; the functional relationship still matters.
- The modality question remains open after Novartis’s acquired Avidity siRNA program moved from promising early results to pivotal failure. The target sits in the nucleus, prompting debate about siRNA suitability. Matteis discloses coverage of Dyne and a prior belief that its antisense approach might be better, supported by stronger splicing effects; “it still needs to be confirmed.” Dyne’s accelerated-approval study reads out early next year.
- The encouraging readthrough is concordance between splicing and function after speculation that endpoint variability or placebo effects contributed to the Novartis failure. Schmidt agrees, while stressing noisy muscle biopsies and functional measures even in placebo-controlled studies. Functional benefit will probably carry the most FDA weight. Dyne’s coming result remains “pretty binary.”